<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Res Methodol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med Res Methodol</journal-id><journal-title-group><journal-title>BMC Medical Research Methodology</journal-title></journal-title-group><issn pub-type="epub">1471-2288</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786573</article-id><article-id pub-id-type="publisher-id">2456</article-id><article-id pub-id-type="doi">10.1186/s12874-025-02456-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymphoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Di Maio</surname><given-names>Danilo</given-names></name><address><email>danilo.di_maio@roche.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mitchell</surname><given-names>S. A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Batson</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Keeney</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Thom</surname><given-names>Howard H. Z.</given-names></name><address><email>Howard.Thom@cliftoninsight.co.uk</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00by1q217</institution-id><institution-id institution-id-type="GRID">grid.417570.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 1269</institution-id><institution>F. Hoffmann-La Roche Ltd, </institution></institution-wrap>Basel, Switzerland </aff><aff id="Aff2"><label>2</label>Mtech Access, Bicester, Oxfordshire UK </aff><aff id="Aff3"><label>3</label>Clifton Insight, Bristol, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0524sp257</institution-id><institution-id institution-id-type="GRID">grid.5337.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7603</institution-id><institution>University of Bristol, </institution></institution-wrap>Bristol, UK </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>30</elocation-id><history><date date-type="received"><day>1</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background and objectives</title><p id="Par1">The National Institute for Health and Care Excellence (England&#x02019;s health technology assessment body) recommend the use of the average treatment effect (ATE) as an estimand for economic evaluations. However there is limited literature on methods to estimate the ATE, particularly in the case of survival outcomes. Single-arm trials and real-world data are playing an increasing role in health technology assessments, particularly in oncology/rare diseases, generating a need for new ATE estimation methods. This study aimed to present the adaptation and utility of this methodology for survival outcomes.</p></sec><sec><title>Methods</title><p id="Par2">The approach is based on a &#x0201c;doubly robust&#x0201d; method combining matching with regression adjustment (Austin 2020) using a Weibull model (lowest Akaike information criteria [AIC] specification) to estimate counterfactual event times. As a case study, we compared mosunetuzumab versus rituximab/bendamustine, as a proxy for rituximab/chemotherapy, in 3L+&#x02009;relapsed/refractory follicular lymphoma. Individual patient data for mosunetuzumab (NCT02500407) and a combination of two rituximab/bendamustine 3L+&#x02009;follicular lymphoma cohorts (NCT02187861/NCT02257567) were used. Endpoints included overall survival (OS) and progression-free survival (PFS). Sensitivity analyses were performed to test robustness to different distributional assumptions (log-normal, log-logistic and exponential) or model specifications (second, third and fourth lowest AIC) for event times.</p></sec><sec><title>Results</title><p id="Par3">The case study found improved PFS (hazard ratio [HR] 0.43 [95% confidence interval (CI): 0.13, 0.91]) and OS (HR 0.30 [95% CI: 0.05, 5.28]) for mosunetuzumab. Consistent findings (HR range 0.25&#x02013;0.47 and 0.21&#x02013;0.50 with all CIs excluding/including 1 for PFS/OS, respectively) were observed in sensitivity analyses.</p></sec><sec><title>Discussion/conclusions</title><p id="Par4">The proposed adaptation expands the range of available approaches for the estimation of the (local) ATE for survival outcomes in health technology assessments using &#x0201c;doubly robust&#x0201d; methods. This approach appeared relatively robust to modelling decisions in our case study.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12874-025-02456-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Indirect treatment comparisons</kwd><kwd>Propensity score matching</kwd><kwd>Regression adjustment</kwd><kwd>Doubly robust</kwd><kwd>Counterfactual</kwd><kwd>ATE</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Follicular lymphoma (FL), a form of low-grade non-Hodgkin lymphoma, has a chronic relapsing disease course with long overall survival (OS) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Patients with FL and a low tumor burden can often be considered for observation only. However, if active treatment is required, obinutuzumab or rituximab in combination with chemotherapy can be administered as initial treatment. After a response to initial therapy, recurrent relapses frequently occur with progressively shorter durations of response to salvage therapy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. There is no standard of care for relapsed/refractory (RR) FL [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] but treatment often includes rituximab and chemotherapy (R-chemo), particularly in later lines of therapy [<xref ref-type="bibr" rid="CR7">7</xref>] because other options are not reimbursed in all markets. New agents for third-line and beyond (3L+) treatment of RR FL, mainly investigated in Phase 1/2 single-arm studies, are emerging [<xref ref-type="bibr" rid="CR8">8</xref>]. This includes mosunetuzumab, a novel CD20/CD3 bispecific antibody (NCT02500407) [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par6">To assess the true causal effects of interventions requires evaluation of the average treatment effect (ATE), i.e. the expected relative effect of a treatment on a randomly selected individual from the population, which can normally be estimated by directly comparing mean outcomes between treated and control groups in randomized controlled trials (RCT) [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The ATE is also the estimand generally preferred by health technology assessment (HTA) bodies, such as England&#x02019;s National Institute for Health and Care Excellence (NICE), for economic evaluations of new interventions [<xref ref-type="bibr" rid="CR13">13</xref>], due to its broader generalizability. Although RCTs represent the gold standard to estimate the ATE, they are not always feasible and, despite treatment effect estimates derived from non-randomized studies being at higher risk of bias [<xref ref-type="bibr" rid="CR14">14</xref>], evidence from single-arm trials and real-world observational data are increasingly used in HTA [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. This is particularly the case in rare diseases or some oncology indications where conducting an RCT may not be possible, patient recruitment may be difficult, or events may take too long to occur [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. These situations necessitate statistical approaches that control for confounding and estimate the counterfactual outcomes in a target population where every patient has received either treatment to evaluate the average causal effect, following Neyman-Rubin&#x02019;s causal framework [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par7">An increasingly popular methods family in observational research uses two regression models, one for the outcome (sometimes referred to as G-formula or Q-model) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and one for treatment exposure (i.e. a propensity score [PS] model) [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. The combination of methods modelling the outcome (often referred to as regression adjustment) [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] and the exposure (i.e. propensity score matching or weighting) [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>] has generally been shown to have superior statistical properties versus individual methods alone, as it can protect against bias from potential misspecification of either model [<xref ref-type="bibr" rid="CR45">45</xref>]. This is often referred to as &#x0201c;double robustness,&#x0201d; an appealing theoretical property which implies that such methods yield consistent estimators if at least one model is correctly specified [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>]. However, they may not always have superior performance to single model strategies when both regression models are mis-specified [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par8">The literature on &#x0201c;doubly robust&#x0201d; methods to estimate the ATE is scarce, particularly for continuous survival outcomes, with few examples of code implementation or application to real case studies. In fact, most studies either focus on the estimation of the average treatment effect on the treated (ATT), i.e. the expected relative effect of a treatment on the individuals who received the treatment, or on outcomes other than survival. There is therefore an increasing need to investigate new statistical methods that minimize the risk of bias and enable estimation of the ATE when individual patient data (IPD) are available to compare survival outcomes between treatments.</p><p id="Par9">Currently available &#x0201c;doubly robust&#x0201d; methods include the augmented inverse probability of treatment weighting (AIPTW) [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref>], empirical likelihood estimation [<xref ref-type="bibr" rid="CR56">56</xref>] or the combination of inverse probability of treatment weighting (IPTW) with G-computation [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. A recently published method by Austin et al. (2020) [<xref ref-type="bibr" rid="CR58">58</xref>] combines nearest neighbor [<xref ref-type="bibr" rid="CR59">59</xref>] or caliper matching [<xref ref-type="bibr" rid="CR60">60</xref>] with different regression adjustment models to estimate the ATT for time-to-event outcomes. By combining design- (matching) and outcome-based methods of bias reduction, this approach can also be considered to belong to the &#x0201c;doubly robust&#x0201d; family [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Owing to the availability of different matching algorithms, this method offers greater flexibility than the currently investigated alternatives, with potential for customization to different dataset characteristics. Furthermore, unlike other popular approaches that rely on a covariate-adjusted outcome model to control for residual imbalances on relative effect estimates after matching/weighting [<xref ref-type="bibr" rid="CR61">61</xref>], by adjusting the IPD twice this method can also adjust for residual imbalances in survival curves. This may be beneficial when studying relative effect measures other than the hazard ratio (HR) (e.g. difference in survival rates or in mean survival times), as well as when adjusted survival curves are needed for subsequent modelling. Moreover, methods relying on outcome imputation are beneficial in terms of statistical power compared to other established methods, such as those modelling treatment exposure only, even when censoring rates are high [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. This may be particularly useful in rare/indolent diseases, such as 3L+&#x02009;FL, where recruiting patients and/or accruing events may be challenging.</p><p id="Par10">This study was inspired by Austin et al. (2020) [<xref ref-type="bibr" rid="CR58">58</xref>] and its objective was twofold: (1) propose an adaptation of their reported method for estimation of the ATE and develop a code example (not available in the original article) to facilitate its adoption; (2) illustrate its implementation in a HTA application context, such as the comparison between two treatments using different data sources. For the latter, the comparison of mosunetuzumab and rituximab plus bendamustine (BR; as a representative for R-chemo) for the 3L+&#x02009;treatment of RR FL was used as a case study.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data sources</title><p id="Par11">The ATE estimation requires availability of IPD for both treatments, which in real-world applications usually come from clinical trial or registry/claims data. For this study, trial data on OS and progression-free survival (PFS) were available and were preferred as they typically represent a higher quality source than registry data [<xref ref-type="bibr" rid="CR64">64</xref>], due to generally stricter enrolment and data collection requirements [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. The source of mosunetuzumab single-agent data was the dose expansion cohort of GO29781 (NCT02500407) [<xref ref-type="bibr" rid="CR9">9</xref>], which included 90 patients with 3L+&#x02009;RR FL, based on a clinical cut-off date of January 2022. The population used to compare mosunetuzumab to BR was a combination of two cohorts of patients with 3L+&#x02009;FL from the BR arms of the CONTRALTO (NCT01724021) [<xref ref-type="bibr" rid="CR67">67</xref>] and GO29365 (NCT02257567) [<xref ref-type="bibr" rid="CR68">68</xref>] trials (<italic>n</italic>&#x02009;=&#x02009;48, latest available cut-off date for both). There were important differences in follow-up between treatment arms. Although this was not unexpected, as CONTRALTO and GO29365 are completed studies whereas GO29781 is still ongoing, this likely had an impact on the difference in censoring rates across arms, particularly given the slowly progressive nature of FL [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par12">To ensure that the patient cohorts used for the analyses were as homogeneous as possible, a filtering procedure based on applying common eligibility/enrolment criteria was adopted. This consisted of excluding patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 from the CONTRALTO and the GO29365 trial cohorts (to align with the inclusion/exclusion criteria of the GO29781 trial) and excluding patients who received more than five prior anticancer regimens from the GO29781 cohort (to align with the populations enrolled in the CONTRALTO and GO29365 trials). This allowed improvement of population overlap prior to conducting any adjustments. In total, 81 and 46 patients were included in the mosunetuzumab and BR arms, respectively. In the case of missing values for categorical or continuous covariates, these were imputed using a simple imputation approach based on the mode or the mean without the missing values, respectively. This was justified by the limited amount of missing data observed across datasets, due to these originating from clinical trials.</p></sec><sec id="Sec4"><title>Statistical approach</title><sec id="Sec5"><title>Propensity score estimation</title><p id="Par13">The propensity score <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{e}_{i}=\text{Pr}\left({z}_{i\:}=1\:\right|{\varvec{x}}_{i\:})$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq1.gif"/></alternatives></inline-formula> is estimated using the following logistic model:<disp-formula id="Equa"><alternatives><tex-math id="M2">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\text{log}\left(\frac{{e}_{i}}{{1-e}_{i}}\right)={\beta\:}_{0}+\:{\varvec{\beta\:}\varvec{x}}_{i}$$\end{document}</tex-math><graphic xlink:href="12874_2025_2456_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par14">Where <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{z}_{i\:}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq2.gif"/></alternatives></inline-formula>is the treatment exposure indicator variable, <inline-formula id="IEq3"><alternatives><tex-math id="M4">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\varvec{x}}_{i\:}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq3.gif"/></alternatives></inline-formula>a vector or relevant covariates for individual <inline-formula id="IEq4"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:i$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq4.gif"/></alternatives></inline-formula>, <inline-formula id="IEq5"><alternatives><tex-math id="M6">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\beta\:}_{0}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq5.gif"/></alternatives></inline-formula> a model intercept and <inline-formula id="IEq6"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\varvec{\beta\:}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq6.gif"/></alternatives></inline-formula> a vector of model coefficients for the parameters <inline-formula id="IEq7"><alternatives><tex-math id="M8">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\varvec{x}}_{i\:}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq7.gif"/></alternatives></inline-formula>. The pre-specified list of prognostic factors and effect modifiers considered for the analysis, ranked by level of priority, was informed by clinical expert opinion (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Expert elicitation was obtained via direct discussions with independent clinical experts. Only variables that could influence outcomes (and potentially treatment exposure) were selected for inclusion in the models; variables that would be associated with exposure only (e.g. instrumental variables) were excluded, to avoid introducing bias in the analyses. The inclusion of selected two-way covariate interaction terms with potential prognostic value (i.e. age and number of prior therapies, age and refractory to last line of therapy and progression of disease within 24 months [POD24] and refractory to last line of therapy), as per consultation with clinical experts, was also considered.</p><p id="Par15">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Prognostic factors and/or effect modifiers considered for inclusion in the analysis, ranked by level of priority<sup>&#x001c2;</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Prognostic factor /effect modifier</th><th align="left">Direction of effect with increasing covariate values*</th><th align="left">Notes</th></tr></thead><tbody><tr><td align="left">
<bold><italic>High priority</italic></bold>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">Number of previous chemotherapeutic (or systemic) agents</td><td align="left">&#x02193;</td><td align="left">E.g., 3 vs. &#x0003e;3 [no clinically established threshold] or median, if categories not reported</td></tr><tr><td align="left">Refractoriness to last previous therapy (yes/no)</td><td align="left">&#x02193;</td><td align="left">E.g. defined as best response progressed/stable disease or relapse&#x02009;&#x0003c;&#x02009;6 months from last therapy</td></tr><tr><td align="left">Refractoriness to any prior aCD20 mAb containing therapy (yes/no)</td><td align="left">&#x02193;</td><td align="left">Also used as proxy for rituximab refractoriness when needed</td></tr><tr><td align="left">Early relapse status (POD24) (yes/no)</td><td align="left">&#x02193;</td><td align="left">Can be defined differently across studies; definition: &#x0201c;from first treatment&#x0201d; should be preferred over &#x0201c;from diagnosis&#x0201d;, as it is aligned with the definition used in the GO29781 trial</td></tr><tr><td align="left">Prior (A)SCT (yes/no)</td><td align="left">&#x02193;</td><td align="left"/></tr><tr><td align="left">Size of the largest lymph node lesion (longest dimension) involved</td><td align="left">&#x02193;</td><td align="left">Highly correlated with bulky disease<sup>1</sup> -&#x0003e; to be prioritized over bulky disease, when possible</td></tr><tr><td align="left">Bulky disease (yes/no)<sup>a</sup></td><td align="left">&#x02193;</td><td align="left"/></tr><tr><td align="left">Follicular lymphoma international prognostic index risk group (high [&#x02265;&#x02009;3] versus intermediate/low [&#x0003c;&#x02009;3])</td><td align="left">&#x02193;</td><td align="left">At study entry; if at diagnosis, limited value in 3&#x000a0;L&#x02009;+&#x02009;and individual components to be prioritized</td></tr><tr><td align="left">Age</td><td align="left">&#x02193;</td><td align="left">Mean, or median if mean not reported, or % &#x02265;60 years (when feasible), if neither reported</td></tr><tr><td align="left">Ann Arbor Stage (III&#x02013;IV vs. I-II)</td><td align="left">&#x02193;</td><td align="left"/></tr><tr><td align="left">High lactate dehydrogenase (yes/no)</td><td align="left">&#x02193;</td><td align="left"/></tr><tr><td align="left">Bone marrow involvement (yes/no, as demonstrated by bone marrow biopsy)</td><td align="left">&#x02193;</td><td align="left">When available, typically is rarely reported</td></tr><tr><td align="left">Low hemoglobin level (yes/no, e.g. &#x0003c;12 [or 12.5] g/dL, or &#x0003c;&#x02009;LLN)</td><td align="left">&#x02193;</td><td align="left"/></tr><tr><td align="left"/><td align="left" colspan="2">&#x02003;&#x02003;&#x02003;<bold><italic>Low priority</italic></bold></td></tr><tr><td align="left">Duration of prior response/time in previous remission/time since completion of last therapy</td><td align="left">&#x02191;</td><td align="left"/></tr><tr><td align="left">Presence of B-symptoms (not that important as they are quite subjective)</td><td align="left">&#x02193;</td><td align="left"/></tr><tr><td align="left">ECOG S (e.g. 1 vs. 0)</td><td align="left">&#x02193;</td><td align="left">The distinction between 0&#x02013;1 and &#x02265;&#x02009;2 carries the greatest prognostic value</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: (A)SCT, autologous stem cell transplant; ECOG PS, Eastern Cooperative Oncology Group performance status; LLN, lower limit of normal. *The arrows indicate the impact on survival times (&#x02193; decreases, &#x02191; increases), i.e. &#x02193; is associated with higher prognostic impact. &#x001c2;Informed by clinical expert opinion</p><p><sup>a</sup>Bulky disease is generally constructed from the size of largest lymph node lesion (longest dimension) involved; as none of the thresholds typically used to define bulky disease have been established as being superior prognostically over the others (based on medical feedback), then adjusting for bulky disease in the analysis should be de-prioritized in favour of size of largest lymph node lesion when information on both is available. It is worth noting that high tumor burden/bulky disease based on GELF criteria can also be reported in some studies. However, this is mainly used to decide between a watch-and-wait and an active treatment approach and its prognostic value is not really recognized by the medical community</p></table-wrap-foot></table-wrap>
</p><p id="Par16">If the coefficients or standard errors (SEs) of the logistic regression model used to estimate the PSs were implausibly large (e.g. over 1,000), indicating excessive treatment group heterogeneity or collinearity issues, the problematic covariate(s) was identified and excluded from the model (eventually not required). The final distribution of estimated PSs was inspected in order to assess the overlap between treatment groups, as well as to identify the presence and frequency of PSs with potentially extreme values, which could create problems during the matching process (Figure&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>).</p></sec><sec id="Sec6"><title>Propensity score matching</title><p id="Par17">Five matching methods were explored: (1) nearest neighbor matching without replacement [<xref ref-type="bibr" rid="CR59">59</xref>]; (2) nearest neighbor matching with replacement [<xref ref-type="bibr" rid="CR59">59</xref>]; (3) optimal pair matching [<xref ref-type="bibr" rid="CR69">69</xref>]; (4) genetic matching [<xref ref-type="bibr" rid="CR70">70</xref>]; and (5) full matching [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. The matching method and PS model that resulted in the optimal covariance balance, i.e. that which minimized the number of imbalanced confounders (overall and within the high priority set), was selected as the preferred approach. Effective sample sizes (ESS) were also compared across methods to ensure the bias-variance trade-off was acceptable.</p></sec><sec id="Sec7"><title>Assessment of covariate balance</title><p id="Par18">Covariate balance was assessed as measured by the absolute standardized mean differences, using a threshold of 0.1, and the complements of overlapping coefficients pre- and post-matching [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec8"><title>Regression adjustment</title><p id="Par19">Regression adjustment was conducted on the matched patient sample in order to estimate the counterfactual outcomes (i.e. missing potential outcomes under treatment for controls and missing potential outcomes under control for treated subjects) required to recover the ATE or a local form of it (i.e. the ATE on a subsample of individuals from the overall population). In fact, the matching method selection may have implications on the interpretation and generalizability of the results, as using a less representative sample may result in a change to the estimand being evaluated [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par20">Unlike Austin et al. (2020) who only imputed potential outcomes under control for each treated patient (as the aim was to estimate the ATT), all counterfactual outcomes were imputed in this case, as the aim was to recover the ATE [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>]. To achieve this, an accelerated failure time (AFT) parametric model was used to regress event times on baseline characteristics:<disp-formula id="Equb"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\text{log}\left({T}_{i}\right)={\beta\:}_{0}+{\varvec{\beta\:}\varvec{x}}_{i}+\sigma\:{\epsilon\:}_{i}$$\end{document}</tex-math><graphic xlink:href="12874_2025_2456_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par21">Where <inline-formula id="IEq8"><alternatives><tex-math id="M10">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{T}_{i}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq8.gif"/></alternatives></inline-formula> is the event time for individual <inline-formula id="IEq9"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:i$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq9.gif"/></alternatives></inline-formula>, <inline-formula id="IEq10"><alternatives><tex-math id="M12">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\sigma\:$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq10.gif"/></alternatives></inline-formula> a scale parameter, <inline-formula id="IEq11"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\epsilon\:}_{i}\:$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq11.gif"/></alternatives></inline-formula>the error terms and <inline-formula id="IEq12"><alternatives><tex-math id="M14">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\beta\:}_{0}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq12.gif"/></alternatives></inline-formula>, <inline-formula id="IEq13"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\varvec{\beta\:}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq13.gif"/></alternatives></inline-formula> and <inline-formula id="IEq14"><alternatives><tex-math id="M16">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\varvec{x}}_{i}$$\end{document}</tex-math><inline-graphic xlink:href="12874_2025_2456_Article_IEq14.gif"/></alternatives></inline-formula> the model intercept, coefficient and covariate values, respectively, as per the notation above.</p><p id="Par22">This modelling approach was selected as it provides additional flexibility and is more straightforward to implement in a code compared with other potential options such as semi-parametric Cox regression models, which require additional steps (i.e. estimation of a baseline hazard and subsequent sampling of event times) [<xref ref-type="bibr" rid="CR58">58</xref>]. Moreover, results from a recent simulation study showed that most methods relying on Cox models may have systematic bias in small samples, even when the model is correctly specified [<xref ref-type="bibr" rid="CR76">76</xref>], indicating that an alternative model may be more appropriate given the sample size of our case study.</p><p id="Par23">A Weibull model was selected as the reference based on its advantageous theoretical properties, e.g. as it was the only model which simultaneously fulfilled both the proportional hazards (PH) and accelerated failure time assumptions, providing sufficient flexibility to capture the relationship between patient characteristics and outcomes under multiple possible scenarios [<xref ref-type="bibr" rid="CR78">78</xref>]. It is worth nothing that other parametric models may have also been potentially suitable candidates; therefore, the impact of selecting alternative models was assessed in scenario analyses.</p><p id="Par24">Although outcome models should preferentially include all risk factors, the overall small sample size in our dataset, as well as the relatively short follow-up in the treated group and the limited number of events observed for some endpoints, warranted the use of a reduced set of covariates, as also highlighted in previous studies [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Similarly, two-way interactions were not considered because of the large number of potential factors for inclusion. Therefore, we aimed to select an optimal model specification that would allow us to best capture the confounder-outcome relationship as observed in the available data. The selection of covariates in the final regression model was performed by comparing the Akaike information criteria (AIC), a score used to determine model performance with a penalty for the number of model parameters, of all combinations of the available covariates [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Excluding the interactions enabled all models to be initially considered for minimum AIC exploration and minimized the potential for overfitting. Different outcome models for the treated and the control groups were allowed and event times estimated to be larger than the maximum follow-up between the treatment groups being compared were censored to avoid extrapolating excessively beyond the range of observed data. Covariates that made the final model unstable (e.g. leading to at least one coefficient SE being excessively high or 0) and prevented it from converging properly (e.g. if no event was observed for one category) were removed from the starting set. In line with the original Austin et al. (2020) method, only a single event time per-patient was imputed, for simplicity (the imputation of multiple event times would have required the additional step of using Rubin&#x02019;s rules to obtain a pooled estimate of the HR SEs) [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par25">The counterfactual outcomes for each group estimated as described above were combined with the respective observed outcomes. The resulting dataset was then used to compare OS and PFS outcomes between treatments using standard survival analysis methods (i.e. Kaplan-Meier (KM) estimators and Cox regression models).</p><p id="Par26">Bootstrapping over the entire matching and regression adjustment procedure, which has the advantage of yielding valid post-selection inference, was used to obtain confidence intervals (CI) (2000 resamples were used to ensure a minimum of 1000 values for the estimation) [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par27">A series of scenario analyses were conducted for the regression adjustment approach to test its robustness to different modeling decisions, such as the use of different distributional assumptions and statistical models for event times. The scenarios explored included the use of alternative AFT parametric survival models for the distribution of event times (Weibull versus log-normal, log-logistic, and exponential). Together, these represent the four most frequently accepted distributions in HTA applications [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Note that other distributions among those commonly considered in HTA [<xref ref-type="bibr" rid="CR85">85</xref>], such as Gompertz, Generalized Gamma, or other more flexible parametric models, could not be explored as these would either (1) likely be implausible for the case study (by modelling &#x0201c;curative-like&#x0201d; scenarios [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>] in the context of a chronic relapsing disease considered incurable [<xref ref-type="bibr" rid="CR7">7</xref>]), (2) be excessively data demanding, or (3) not be supported by the package used to simulate event times. Also, alternative outcome regression model specifications were explored (lowest AIC versus second, third and fourth-lowest AIC).</p></sec><sec id="Sec9"><title>Software</title><p id="Par28">All analyses were performed using the R statistical programming language [<xref ref-type="bibr" rid="CR88">88</xref>]. Model selection by stepwise backward-testing was conducted using the stepAIC function [<xref ref-type="bibr" rid="CR79">79</xref>]. The &#x02018;MatchIt&#x02019; package was used to estimate the propensity score and for matching [<xref ref-type="bibr" rid="CR89">89</xref>]. Covariate balance was assessed using the cobalt package [<xref ref-type="bibr" rid="CR90">90</xref>]. Survival analysis was conducted and plots were created using the R packages &#x02018;survival&#x02019; and &#x02018;survminer&#x02019; [<xref ref-type="bibr" rid="CR91">91</xref>]. Simulation of survival outcomes for the regression adjustment was performed using the R package &#x02018;survParamSim&#x02019; [<xref ref-type="bibr" rid="CR92">92</xref>]. Restricted mean survival times (RMST) were estimated using the survRM2 R package (at the shortest maximum follow-up across arms, as per default option). The analysis R code is provided in the supplementary information.</p></sec></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Model and matching algorithm selection</title><p id="Par29">A final model including all linear predictors plus selected clinically relevant interaction terms (see Methods), was selected to estimate the propensity score, as it yielded better covariate balance compared to a model without interactions (Table&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref> &#x00026; Figure S2). Covariate balance achieved with the different matching methods is displayed in love plots in Figure S3. The final sample sizes after nearest neighbor matching without replacement, genetic matching and optimal pair matching were 92 patients (as no weights are involved). The final ESS after nearest neighbor matching with replacement was 81 patients in the mosunetuzumab arm and ~&#x02009;9.9 pseudo-patients in the BR arm. The final ESS after full matching (ATE) was ~&#x02009;49.3 pseudo-patients in the mosunetuzumab arm and ~&#x02009;18.9 pseudo-patients in the BR arm. Balance after nearest neighbor matching without replacement and genetic matching was quite poor on several covariates and nearly indistinguishable across the two methods. Balance after full matching (ATE) and nearest neighbor matching with replacement was also fairly poor. Optimal pair matching instead resulted in a better, though still not fully achieved, covariate balance compared with all other matching methods explored. Because of this, optimal pair matching was selected as the matching method of preference for the comparison. Although covariate balance post-matching was improved significantly for many prognostic factors (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), residual imbalances for several factors were observed, most of which were, notably, in favor of the BR arm from a prognostic perspective. This is not necessarily unexpected, given the small sample size of the BR arm, as well as the fact that the CONTRALTO and GO29365 trials (being clinical studies focusing on the broader RR population) enrolled comparatively healthier patients (i.e. less refractory and less heavily pre-treated) vs. GO29781, which instead prioritized enrolment of patients with no other suitable treatment options.</p><p id="Par30">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of baseline characteristics after optimal pair matching</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variable</th><th align="left" colspan="2">Mosunetuzumab (SS&#x02009;=&#x02009;46)</th><th align="left" colspan="2">Rituximab plus bendamustine (SS&#x02009;=&#x02009;46)</th><th align="left" rowspan="2">aSMD</th><th align="left" rowspan="2">Complement of the overlapping coefficient</th></tr><tr><th align="left">Mean</th><th align="left">SD</th><th align="left">Mean</th><th align="left">SD</th></tr></thead><tbody><tr><td align="left">Age (mean)</td><td char="." align="char">62.7</td><td char="." align="char">12.2</td><td char="." align="char">63.3</td><td char="." align="char">11.2</td><td char="." align="char">0.04</td><td char="." align="char">0.15</td></tr><tr><td align="left">ECOG PS (1 vs. 0) (%)</td><td char="." align="char">32.6</td><td char="." align="char">46.9</td><td char="." align="char">26.1</td><td char="." align="char">43.9</td><td char="." align="char">0.13</td><td char="." align="char">0.07</td></tr><tr><td align="left">FLIPI&#x02009;&#x02265;&#x02009;3 (Yes) (%)</td><td char="." align="char">47.8</td><td char="." align="char">50.0</td><td char="." align="char">50.0</td><td char="." align="char">50.0</td><td char="." align="char">0.04</td><td char="." align="char">0.02</td></tr><tr><td align="left">Ann Arbor Stage III/IV (Yes) (%)</td><td char="." align="char">73.9</td><td char="." align="char">43.9</td><td char="." align="char">80.4</td><td char="." align="char">39.7</td><td char="." align="char">0.15</td><td char="." align="char">0.07</td></tr><tr><td align="left">Prior therapies&#x02009;&#x02265;&#x02009;3 (%)</td><td char="." align="char">63.0</td><td char="." align="char">48.3</td><td char="." align="char">60.9</td><td char="." align="char">48.8</td><td char="." align="char">0.04</td><td char="." align="char">0.02</td></tr><tr><td align="left">Refractory to last line (Yes) (%)</td><td char="." align="char">60.9</td><td char="." align="char">48.8</td><td char="." align="char">47.8</td><td char="." align="char">50.0</td><td char="." align="char">0.28</td><td char="." align="char">0.13</td></tr><tr><td align="left">Refractory to any prior anti-CD20 mAb containing regimen (Yes) (%)</td><td char="." align="char">76.1</td><td char="." align="char">42.7</td><td char="." align="char">69.6</td><td char="." align="char">46.0</td><td char="." align="char">0.15</td><td char="." align="char">0.07</td></tr><tr><td align="left">Double refractory (Yes) (%)</td><td char="." align="char">47.8</td><td char="." align="char">50.0</td><td char="." align="char">45.7</td><td char="." align="char">49.8</td><td char="." align="char">0.04</td><td char="." align="char">0.02</td></tr><tr><td align="left">POD24 (Yes) (%)</td><td char="." align="char">52.2</td><td char="." align="char">50.0</td><td char="." align="char">47.8</td><td char="." align="char">50.0</td><td char="." align="char">0.09</td><td char="." align="char">0.04</td></tr><tr><td align="left">Bone marrow involvement (yes) (%)</td><td char="." align="char">28.3</td><td char="." align="char">45.0</td><td char="." align="char">26.1</td><td char="." align="char">43.9</td><td char="." align="char">0.05</td><td char="." align="char">0.02</td></tr><tr><td align="left">Prior ASCT (Yes) (%)</td><td char="." align="char">13.0</td><td char="." align="char">33.7</td><td char="." align="char">6.5</td><td char="." align="char">24.7</td><td char="." align="char">0.16</td><td char="." align="char">0.07</td></tr><tr><td align="left">Size of the largest node lesion [cm] (mean)</td><td char="." align="char">5.4</td><td char="." align="char">2.6</td><td char="." align="char">5.7</td><td char="." align="char">3.3</td><td char="." align="char">0.13</td><td char="." align="char">0.09</td></tr><tr><td align="left">Low Hgb (Yes) (%)</td><td char="." align="char">30.4</td><td char="." align="char">46.0</td><td char="." align="char">30.4</td><td char="." align="char">46.0</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td></tr><tr><td align="left">High LDH (Yes) (%)</td><td char="." align="char">34.8</td><td char="." align="char">47.6</td><td char="." align="char">32.6</td><td char="." align="char">46.9</td><td char="." align="char">0.04</td><td char="." align="char">0.02</td></tr><tr><td align="left">Time since completion of last therapy [months] (mean)</td><td char="." align="char">16.3</td><td char="." align="char">19.9</td><td char="." align="char">26.0</td><td char="." align="char">31.9</td><td char="." align="char">0.57</td><td char="." align="char">0.12</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ASCT, autologous stem cell transplant; aSMD, absolute standardised mean difference; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FLIPI, Follicular lymphoma international prognostic index; Hgb, hemoglobin; LDH, lactate dehydrogenase; POD24, Progression of disease within 24 months; SS, sample size. Balanced (defined as &#x0003c;&#x02009;0.1 for aSMD)</p></table-wrap-foot></table-wrap>
</p><p id="Par31">Regression parameters for all final outcome models explored are reported in Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>. The covariates that had to be removed from the starting set for each treatment and outcome model are reported in the R code available in the supplementary information. The main reason for model instability or convergence issues was the lack of observed events for one category of a binary covariate. It is worth noting that the direction of the coefficients in the final models was generally in line with the anticipated prognostic impact of the variables included.</p></sec><sec id="Sec12"><title>Indirect comparison results</title><p id="Par32">A summary of the OS and PFS HR and RMST difference outcomes for mosunetuzumab versus BR assessed using the matching plus regression adjustment approach is provided in Tables&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, respectively. Results from unadjusted and matched (with subsequent covariate adjustment for residual imbalances in the post-matching outcome model) [<xref ref-type="bibr" rid="CR62">62</xref>] samples are presented in Tables&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and <xref rid="MOESM1" ref-type="media">S4</xref>, respectively,&#x000a0;in the supplementary appendix, which also includes additional RMST and survival estimates for the matching plus regression adjustment scenarios explored in Table <xref rid="MOESM1" ref-type="media">S5</xref>. There were extremely high levels of uncertainty associated with the HR and RMST difference estimates in the analyses of OS, which was anticipated due to the low number of events observed in the datasets for both treatment arms.</p><p id="Par33">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of HR matching plus regression adjustment results for mosunetuzumab versus BR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Method for estimating HR</th><th align="left" colspan="2">HR (95% CI)</th></tr><tr><th align="left">OS</th><th align="left">PFS</th></tr></thead><tbody><tr><td align="left">Reference case (lowest AIC and assuming Weibull distribution of event times)</td><td char="." align="char">0.30 (0.05, 5.28)</td><td char="." align="char">0.43 (0.13, 0.91)</td></tr><tr><td align="left">Regression adjustment (second lowest AIC model* and assuming Weibull distribution of event times)</td><td char="." align="char">0.41 (0.06, 6.47)</td><td char="." align="char">0.44 (0.13, 0.97)</td></tr><tr><td align="left">Regression adjustment (third lowest AIC model* and assuming Weibull distribution of event times))</td><td char="." align="char">0.21 (0.05, 5.67)</td><td char="." align="char">0.45 (0.11, 0.96)</td></tr><tr><td align="left">Regression adjustment (fourth lowest AIC model* and assuming Weibull distribution of event times))</td><td char="." align="char">0.39 (0.07, 5.65)</td><td char="." align="char">0.42 (0.13, 0.95)</td></tr><tr><td align="left">Regression adjustment (lowest AIC, assuming log-normal distribution of event times)</td><td char="." align="char">0.27 (0.04, 1.83)</td><td char="." align="char">0.28 (0.11, 0.88)</td></tr><tr><td align="left">Regression adjustment (lowest AIC, assuming log-logistic distribution of event times)</td><td char="." align="char">0.29 (0.06, 2.46)</td><td char="." align="char">0.25 (0.11, 0.93)</td></tr><tr><td align="left">Regression adjustment (lowest AIC, assuming exponential distribution of event times)</td><td char="." align="char">0.50 (0.07, 4.16)</td><td char="." align="char">0.47 (0.17, 0.87)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AIC, Akaike information criterion; BR, rituximab plus bendamustine; CI, confidence interval; HR, hazard ratio; OS, overall survival</p><p>HRs presented for the comparison of mosunetuzumab versus rituximab plus bendamustine. HRs&#x02009;&#x0003c;&#x02009;1 favor mosunetuzumab</p><p>*Without convergence issues</p></table-wrap-foot></table-wrap>
</p><p id="Par34">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of RMST difference matching plus regression adjustment results for mosunetuzumab versus BR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Method for estimating RMST difference</th><th align="left" colspan="2">RMST difference (95% CI)</th></tr><tr><th align="left">OS</th><th align="left">PFS</th></tr></thead><tbody><tr><td align="left">Reference case (lowest AIC and assuming Weibull distribution of event times)</td><td char="&#x02212;" align="char">5.00 (-5.40, 11.56)</td><td char="&#x02212;" align="char">7.57 (-0.29, 14.70)</td></tr><tr><td align="left">Regression adjustment (second lowest AIC model* and assuming Weibull distribution of event times)</td><td char="&#x02212;" align="char">4.46 (-5.99, 11.12)</td><td char="&#x02212;" align="char">7.59 (-0.55, 14.96)</td></tr><tr><td align="left">Regression adjustment (third lowest AIC model* and assuming Weibull distribution of event times))</td><td char="&#x02212;" align="char">5.82 (-6.06, 11.49)</td><td char="&#x02212;" align="char">6.54 (-1.00, 15.25)</td></tr><tr><td align="left">Regression adjustment (fourth lowest AIC model* and assuming Weibull distribution of event times))</td><td char="&#x02212;" align="char">4.03 (-5.58, 9.13)</td><td char="&#x02212;" align="char">6.88 (-0.76, 14.38)</td></tr><tr><td align="left">Regression adjustment (lowest AIC, assuming log-normal distribution of event times)</td><td char="&#x02212;" align="char">4.15 (-1.93, 11.95)</td><td char="&#x02212;" align="char">9.34 (-1.01, 15.52)</td></tr><tr><td align="left">Regression adjustment (lowest AIC, assuming log-logistic distribution of event times)</td><td char="&#x02212;" align="char">3.29 (-3.14, 10.28)</td><td char="&#x02212;" align="char">9.57 (-0.67, 15.39)</td></tr><tr><td align="left">Regression adjustment (lowest AIC, assuming exponential distribution of event times)</td><td char="&#x02212;" align="char">2.20 (-15.19, 7.17)</td><td char="&#x02212;" align="char">6.47 (-0.62, 13.51)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AIC, Akaike information criterion; BR, rituximab plus bendamustine; CI, confidence interval; OS, overall survival; RMST, restricted mean survival time</p><p>RMST differences presented for the comparison of mosunetuzumab versus rituximab plus bendamustine. RMST difference&#x02009;&#x0003e;&#x02009;1 favor mosunetuzumab</p><p>*Without convergence issues</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Overall survival</title><p id="Par35">The OS KM plots for the unadjusted and optimal-pair matching analyses, as well as those generated using the reference matching plus regression adjustment approach are presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The KM plots for all the other modelling scenarios explored are presented in Figure S4. The HRs for OS numerically favored mosunetuzumab versus BR (HR&#x02009;&#x0003c;&#x02009;1) in all analyses using the matching plus regression adjustment method (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The HR (95% CI) obtained using the reference matching plus regression adjustment model was 0.30 (0.05, 5.28). More favorable (lower) HRs were obtained for the regression adjustments assuming log-normal distribution of event times (0.27 [0.04, 1.83]), assuming log-logistic distribution of event times (0.29 [0.06, 2.46]), and using the third lowest AIC model without convergence issues (0.21 [0.05, 5.67]). Less favorable (higher) HRs were obtained for the regression adjustments using the second lowest AIC model without convergence issues (0.41 [0.06, 6.47]), using the fourth lowest AIC model without convergence issues (0.39 [0.07, 5.65]), and assuming exponential distribution of event times (0.50 [0.07, 4.16]). The RMST difference for OS in the reference matching plus regression adjustment model was 5.00 (-5.40, 11.56) months with the point estimates ranging from 2.20 to 5.82 months across sensitivity analyses. The RMST difference results for OS were overall concordant with the HR results, in that they numerically favored or slightly favored mosunetuzumab versus BR (RMST difference&#x02009;&#x0003e;&#x02009;1) in all analyses, but featured wide CIs which systematically crossed zero, therefore indicating large uncertainty around the estimated differences.</p><p id="Par36">
<fig id="Fig1"><label>Fig. 1</label><caption><p>KM plots of OS for unadjusted (<bold>A</bold>), optimal pair matched (<bold>B</bold>) and matching plus regression adjustment samples (<bold>C</bold>)</p></caption><graphic xlink:href="12874_2025_2456_Fig1_HTML" id="d33e1308"/></fig>
</p></sec><sec id="Sec14"><title>Progression-free survival</title><p id="Par37">The PFS KM plots for the unadjusted and optimal-pair matching analyses, as well as those generated using the reference matching plus regression adjustment approach, are presented in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. The KM plots for all other scenarios are presented in Figure S4. The HRs for PFS were &#x0003c;&#x02009;1 in all analyses using the matching plus regression adjustment method, showing a greater numerical benefit in PFS for mosunetuzumab compared to BR (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). A HR (95% CI) of 0.43 (0.13, 0.91) was obtained using the reference matching plus regression adjustment model. The adjustments assuming log-logistic distribution of event times, log-normal distribution of event times, and using the fourth lowest AIC model without convergence issues had more favorable (lower) HR (95% CI) values of 0.25 (0.11, 0.93), 0.28 (0.11, 0.88), and 0.42 (0.13, 0.95), respectively, compared with the reference matching plus regression adjustment model. In contrast, slightly less favorable (higher) HRs (95% CI) were obtained with the adjustments using the second (0.44 [0.13, 0.97]) and third lowest AIC model without convergence issues (0.45 [0.11, 0.96]), as well as the method assuming exponential distribution of event times (0.47 [0.17, 0.87]). The CIs associated with the HRs did not cross 1 for any of the matching plus regression adjustment scenarios considered. The RMST difference for PFS in the reference matching plus regression adjustment model was 7.57 (&#x02011;0.29, 14.70) months with the point estimates ranging from 6.47 to 9.57 months across sensitivity analyses. The RMST difference results for PFS were overall broadly concordant with the HR results, in that they numerically strongly favored mosunetuzumab versus BR (RMST difference&#x02009;&#x0003e;&#x02009;1) in all analyses, although the respective CIs around the estimated differences marginally crossed 1 in all scenarios considered.</p><p id="Par38">
<fig id="Fig2"><label>Fig. 2</label><caption><p>KM plots of PFS for unadjusted (<bold>A</bold>), optimal pair matched (<bold>B</bold>) and matching plus regression adjustment samples (<bold>C</bold>)</p></caption><graphic xlink:href="12874_2025_2456_Fig2_HTML" id="d33e1338"/></fig>
</p><p id="Par39">The survival curves (easier to interpret in this case due to the higher number of events) for mosunetuzumab were fairly similar, regardless of whether Weibull or exponential distributions were assumed. However, these differed from those assuming log-normal or log-logistic distributions, which in turn were fairly similar to each other and showed a trend towards a plateau. This may reflect the intrinsic distributional features of these models, as it was not evident in the curves generated using the Weibull model with the fourth lowest AIC, which shared the same specification. This is also in line with what was observed for the BR group, where the survival curves for log-normal or log-logistic distributions had a more similar shape than those obtained assuming exponential or Weibull distributions (third lowest AIC), when all models shared the same specification.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par40">The objective of this study was to adapt a matching plus regression adjustment approach for the estimation of the ATE for survival outcomes, as well as to test the robustness of the method to different modelling decisions through a case study in a rare disease setting. We did not intend to provide an overview of available methods for causal inference of survival outcomes (refer to Denz et al. [2023] [<xref ref-type="bibr" rid="CR76">76</xref>] for a recent review), nor to compare its performance with that of other methods, as this warrants a thorough simulation study under multiple different data generating assumptions.</p><p id="Par41">In addition to focusing on the ATE, our adaptation differs from the method proposed by Austin et al. (2020) in several ways. While outcome models were fitted separately to both matched patient groups to improve population overlap and reduce the amount of extrapolation beyond observed data when estimating the counterfactual outcomes, we allowed variability between outcome models in the final selection of covariates. Although Austin et al. (2020) did not explore this possibility, presumably due to the larger sample sizes used in their simulation and case study, we consider this an appropriate strategy in applications involving sparse datasets. By allowing more flexibility and not forcing the regression models to share the same specification, there is no need to assume that the covariate-outcome relationship in both treatment groups is best captured using a common model structure, which may not hold true when sample sizes and/or number of events are limited or data maturity differs across arms. We used an AIC-based approach for the final model selection; more sophisticated machine learning methods [<xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR95">95</xref>] were not considered for simplicity, although they represent valuable strategies for when less sparse datasets are available and interaction terms can be included. Moreover, we censored event times estimated to be larger than the maximum follow-up between treatment groups. Although this differs from the Austin et al. (2020) method, their simulation study did not have imbalances in follow-up across treatments and their real-world case study dataset was close to full data maturity. This represents a somewhat idealized condition, which is often not encountered in HTA (e.g. in external control studies) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. We thus consider this approach to be appropriate for our case and similar data maturity situations, particularly when imperfect matching (i.e. one patient group has an overall poorer health status) is an issue, as this may exacerbate the risk that some predicted event times fall excessively beyond the range of observed data. With imperfect matching, using stricter censoring thresholds may cause the undue censoring of informative event times, e.g. if these were predicted for patients in better health had they been part of the sicker group. In fact, when the matched arm with better health has longer follow-up, the counterfactual times for this arm are more likely to be censored compared to those for the other arm, creating an imbalance. However, with more comparable follow-up between arms (e.g. when comparing treatments within the same data source) and greater data maturity, avoiding censoring event times may be useful, as it may help detect if a regression model has major misspecification issues.</p><p id="Par42">Two main findings can be drawn from our case study. Firstly, despite variability in the HRs, the conclusions of our comparison were robust to variation of different assumptions and model specifications used for the outcome regressions. The observed variability is not surprising [<xref ref-type="bibr" rid="CR97">97</xref>], as our matched sample featured residual imbalances and we could not include all potentially relevant covariates in the outcome models. Nevertheless, all results showed a greater separation between the survival curves, in line with the difference in prognostic variables between groups post-matching, as well as the increase in sample size compared to the original matched sample. These consistently indicated longer PFS (particularly after 16&#x02013;20 months) and hinted toward a potential numerical OS benefit with mosunetuzumab; however, this remains extremely uncertain, which is to be expected for this indication and follow-up, cautioning against overinterpreting the trends observed in the analyses. Although imputing multiple counterfactual outcomes may have helped increase precision and reduce uncertainty [<xref ref-type="bibr" rid="CR98">98</xref>], it would not have fundamentally altered the analysis conclusions given the estimated PFS/OS HR CIs [<xref ref-type="bibr" rid="CR98">98</xref>], so it was not considered. Secondly, our scenario analyses suggested that the selection of the event time parametric distribution model may have an impact on the ensuing survival estimates (as expected from a method explicitly modeling outcomes) [<xref ref-type="bibr" rid="CR58">58</xref>], particularly in cases where distributions may differ by treatment. However, in practical applications the &#x0201c;correct&#x0201d; event time distribution is rarely, if ever, known. A potential approach to inform the parametric distribution prioritization may rely on fitting different models by treatment on the matched sample and assessing the best visual/statistical fit to the data, potentially followed by clinical validation, as per standard practice in cost-effectiveness modelling [<xref ref-type="bibr" rid="CR85">85</xref>]. When using these estimates to inform economic models, especially those driven by survival curves, this would also help reduce the uncertainty in cost-effectiveness results, and ultimately decision-making, due to the variability between different modeling scenarios. On the other hand, by using the same distributional assumption for both treatments and combining predicted with observed outcomes, the overall bias may be limited and potentially cancelled out, especially when a common survival distribution can be reasonably assumed.</p><p id="Par43">Our study has limitations. Firstly, the deliberate selection of a challenging and sparse dataset for our HTA case study may limit the generalizability of these findings to other contexts, e.g. less marked and/or more heterogeneous treatment effect differences. Secondly, we were unable to examine how different our &#x0201c;local&#x0201d; ATE results would be from the ATE estimates, as the small control group ESS yielded by full matching prevented us from reliably estimating them. Finally, the clinical disease course and the overall small sample size and sparse nature of the dataset, as well as the current implementation of the survParamSim package, limited the parametric distribution functions of event times we had available to test and the use of Cox regression to estimate survival times was not tested. However, assuming that the time-to-event generating process can be described using a Cox PH model is often an oversimplification [<xref ref-type="bibr" rid="CR76">76</xref>], which frequently does not hold in HTA applications [<xref ref-type="bibr" rid="CR99">99</xref>], despite reflecting assumptions made by most researchers.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par44">In summary, our case study findings were relatively robust to modelling decisions and the proposed adaptation may represent a suitable indirect comparison approach for estimation of the (local) ATE for survival outcomes, offering important benefits in HTA applications. By allowing estimation of &#x0201c;doubly adjusted&#x0201d; (and thus theoretically less biased) survival curves, it may be used to subsequently perform parametric survival extrapolation over a lifetime horizon (a frequent requirement in cost-effectiveness analyses), potentially yielding more robust long-term survival estimates and reducing the uncertainty in the incremental cost-effectiveness ratio. This may be especially beneficial when the PH assumption is unlikely to hold and independent modelling of survival curves between treatments is warranted. However, consideration should be given to the selection of the most appropriate parametric model(s), as the event time distributional assumptions used may have an impact on survival estimates and ultimately cost-effectiveness results.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12874_2025_2456_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Sandro Gsteiger and Michael Seo for their thorough pair of eyes and constructive feedback on the manuscript drafting and revision of the analysis R-code.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>DDM was involved in the conception and design of the work, analysis and interpretation of data, and drafting and reviewing the manuscript. SM was involved in the design of the work, interpretation of data, and drafting and reviewing the manuscript. SB was involved in the design of the work, interpretation of data, and drafting and reviewing the manuscript. EK was involved in the interpretation of data and drafting and reviewing the manuscript. HT was involved in the interpretation of data and drafting and reviewing the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by F. Hoffmann-La Roche Ltd.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>For eligible studies qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing this request platform is Vivli, at <ext-link ext-link-type="uri" xlink:href="https://vivli.org/ourmember/roche/">https://vivli.org/ourmember/roche/</ext-link>. For up-to-date details on Roche&#x02019;s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see <ext-link ext-link-type="uri" xlink:href="https://go.roche.com/data_sharing">https://go.roche.com/data_sharing</ext-link>.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par45">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par46">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par47">DDM is an employee of, and is an equity holder in, F. Hoffmann-La Roche Ltd. SM and SB are employees of Mtech Access, who received consultancy payments from F. Hoffmann-La Roche Ltd for the purposes of this study. EK is an employee of Clifton Insight who have received consultancy fees from Pfizer, Roche, Lundbeck, Amicus, Bayer, Merck, Eisai, Novo Nordisk, Novartis, and Daiichi-Sankyo. HT is an equity holder in Clifton Insight who have received consultancy fees from Pfizer, Roche, Lundbeck, Amicus, Bayer, Merck, Eisai, Novo Nordisk, Novartis, and Daiichi-Sankyo.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>3L+</term><def><p id="Par48">Third-line and beyond</p></def></def-item><def-item><term>AFT</term><def><p id="Par49">Accelerated failure time</p></def></def-item><def-item><term>AIC</term><def><p id="Par50">Akaike information criteria</p></def></def-item><def-item><term>AIPTW</term><def><p id="Par51">Augmented inverse probability of treatment weighting</p></def></def-item><def-item><term>ATE</term><def><p id="Par52">Average treatment effect</p></def></def-item><def-item><term>ATT</term><def><p id="Par53">Average treatment effect on the treated</p></def></def-item><def-item><term>BR</term><def><p id="Par54">Rituximab plus bendamustine</p></def></def-item><def-item><term>CI</term><def><p id="Par55">Confidence intervals</p></def></def-item><def-item><term>ECOG PS</term><def><p id="Par56">Eastern Cooperative Oncology Group Performance Status</p></def></def-item><def-item><term>ESS</term><def><p id="Par57">Effective sample sizes</p></def></def-item><def-item><term>FL</term><def><p id="Par58">Follicular lymphoma</p></def></def-item><def-item><term>HR</term><def><p id="Par59">Hazard ratio</p></def></def-item><def-item><term>HTA</term><def><p id="Par60">Health technology assessment</p></def></def-item><def-item><term>IPD</term><def><p id="Par61">Individual patient data</p></def></def-item><def-item><term>IPTW</term><def><p id="Par62">Inverse probability of treatment weighting</p></def></def-item><def-item><term>KM</term><def><p id="Par63">Kaplan-Meier</p></def></def-item><def-item><term>NICE</term><def><p id="Par64">National Institute for Health and Care Excellence</p></def></def-item><def-item><term>OS</term><def><p id="Par65">Overall survival</p></def></def-item><def-item><term>PFS</term><def><p id="Par66">Progression-free survival</p></def></def-item><def-item><term>POD24</term><def><p id="Par67">Progression of disease within 24 months</p></def></def-item><def-item><term>PH</term><def><p id="Par68">Proportional hazards</p></def></def-item><def-item><term>PS</term><def><p id="Par69">Propensity score</p></def></def-item><def-item><term>R-chemo</term><def><p id="Par70">Rituximab and chemotherapy</p></def></def-item><def-item><term>RCT</term><def><p id="Par71">Randomized controlled trials</p></def></def-item><def-item><term>RMST</term><def><p id="Par72">Restricted mean survival time</p></def></def-item><def-item><term>RR</term><def><p id="Par73">Relapsed refractory</p></def></def-item><def-item><term>SE</term><def><p id="Par74">Standard errors</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Rodgers TD, Barr PM. Management of relapsed follicular lymphoma. Annals Lymphoma. 2021;5.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Horning</surname><given-names>SJ</given-names></name><name><surname>Hoppe</surname><given-names>RT</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Sigal</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Improvements in observed and relative survival in follicular grade 1&#x02013;2 lymphoma during 4 decades: the Stanford University experience</article-title><source>Blood</source><year>2013</year><volume>122</volume><issue>6</issue><fpage>981</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-03-491514</pub-id><pub-id pub-id-type="pmid">23777769</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1&#x02013;2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981&#x02013;7.<pub-id pub-id-type="pmid">23777769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Rivas-Delgado</surname><given-names>A</given-names></name><name><surname>Magnano</surname><given-names>L</given-names></name><name><surname>Moreno-Vel&#x000e1;zquez</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>O</given-names></name><name><surname>Nadeu</surname><given-names>F</given-names></name><name><surname>Mozas</surname><given-names>P</given-names></name><etal/></person-group><article-title>Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the Rituximab era</article-title><source>Br J Haematol</source><year>2019</year><volume>184</volume><issue>5</issue><fpage>753</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/bjh.15708</pub-id><pub-id pub-id-type="pmid">30515755</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Rivas-Delgado A, Magnano L, Moreno-Vel&#x000e1;zquez M, Garc&#x000ed;a O, Nadeu F, Mozas P, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the Rituximab era. Br J Haematol. 2019;184(5):753&#x02013;9.<pub-id pub-id-type="pmid">30515755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Kanters</surname><given-names>S</given-names></name><name><surname>Ball</surname><given-names>G</given-names></name><name><surname>Kahl</surname><given-names>B</given-names></name><name><surname>Wiesinger</surname><given-names>A</given-names></name><name><surname>Limbrick-Oldfield</surname><given-names>EH</given-names></name><name><surname>Sudhindra</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical outcomes in patients relapsed/refractory after &#x02265;&#x02009;2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis</article-title><source>BMC Cancer</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/s12885-023-10546-6</pub-id><pub-id pub-id-type="pmid">36690960</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kanters S, Ball G, Kahl B, Wiesinger A, Limbrick-Oldfield EH, Sudhindra A, et al. Clinical outcomes in patients relapsed/refractory after &#x02265;&#x02009;2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. BMC Cancer. 2023;23(1):74.<pub-id pub-id-type="pmid">36690960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Dreyling</surname><given-names>M</given-names></name><name><surname>Ghielmini</surname><given-names>M</given-names></name><name><surname>Rule</surname><given-names>S</given-names></name><name><surname>Salles</surname><given-names>G</given-names></name><name><surname>Ladetto</surname><given-names>M</given-names></name><name><surname>Tonino</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><issue>3</issue><fpage>298</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.11.008</pub-id><pub-id pub-id-type="pmid">33249059</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298&#x02013;308.<pub-id pub-id-type="pmid">33249059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Salles</surname><given-names>G</given-names></name></person-group><article-title>How do I sequence therapy for follicular lymphoma?</article-title><source>Hematology</source><year>2020</year><volume>2020</volume><issue>1</issue><fpage>287</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1182/hematology.2020000156</pub-id><pub-id pub-id-type="pmid">33275688</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Salles G. How do I sequence therapy for follicular lymphoma? Hematology. 2020;2020(1):287&#x02013;94.<pub-id pub-id-type="pmid">33275688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>A</given-names></name><name><surname>Jacobsen</surname><given-names>E</given-names></name></person-group><article-title>Follicular lymphoma: 2020 update on diagnosis and management</article-title><source>Am J Hematol</source><year>2020</year><volume>95</volume><issue>3</issue><fpage>316</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/ajh.25696</pub-id><pub-id pub-id-type="pmid">31814159</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316&#x02013;27.<pub-id pub-id-type="pmid">31814159</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanel</surname><given-names>W</given-names></name><name><surname>Epperla</surname><given-names>N</given-names></name></person-group><article-title>Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies</article-title><source>J Hematol Oncol</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>104</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01113-2</pub-id><pub-id pub-id-type="pmid">34193230</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hanel W, Epperla N. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol. 2021;14(1):104.<pub-id pub-id-type="pmid">34193230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Budde</surname><given-names>LE</given-names></name><name><surname>Sehn</surname><given-names>LH</given-names></name><name><surname>Matasar</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>SJ</given-names></name><name><surname>Assouline</surname><given-names>S</given-names></name><name><surname>Giri</surname><given-names>P</given-names></name><etal/></person-group><article-title>Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><issue>8</issue><fpage>1055</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00335-7</pub-id><pub-id pub-id-type="pmid">35803286</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055&#x02013;65.<pub-id pub-id-type="pmid">35803286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Estimation of average treatment effect based on a multi-index propensity score</article-title><source>BMC Med Res Methodol</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>337</fpage><pub-id pub-id-type="doi">10.1186/s12874-022-01822-3</pub-id><pub-id pub-id-type="pmid">36577950</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Xu J, Wei K, Wang C, Huang C, Xue Y, Zhang R, et al. Estimation of average treatment effect based on a multi-index propensity score. BMC Med Res Methodol. 2022;22(1):337.<pub-id pub-id-type="pmid">36577950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Chakrabortty</surname><given-names>A</given-names></name><name><surname>Ananthakrishnan</surname><given-names>AN</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name></person-group><article-title>Estimating average treatment effects with a double-index propensity score</article-title><source>Biometrics</source><year>2020</year><volume>76</volume><issue>3</issue><fpage>767</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/biom.13195</pub-id><pub-id pub-id-type="pmid">31797368</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Cheng D, Chakrabortty A, Ananthakrishnan AN, Cai T. Estimating average treatment effects with a double-index propensity score. Biometrics. 2020;76(3):767&#x02013;77.<pub-id pub-id-type="pmid">31797368</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Schaubel</surname><given-names>DE</given-names></name></person-group><article-title>Estimating the average treatment effect on survival based on observational data and using partly conditional modeling</article-title><source>Biometrics</source><year>2017</year><volume>73</volume><issue>1</issue><fpage>134</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/biom.12542</pub-id><pub-id pub-id-type="pmid">27192660</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gong Q, Schaubel DE. Estimating the average treatment effect on survival based on observational data and using partly conditional modeling. Biometrics. 2017;73(1):134&#x02013;44.<pub-id pub-id-type="pmid">27192660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Faria R, Hernandez Alava M, Manca A, Wailoo AJ. NICE DSU Technical Support Document 17: The use of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nicedsu.org.uk">http://www.nicedsu.org.uk</ext-link></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">NICE. NICE DSU Technical Support Document 17. The use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data 2015. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.sheffield.ac.uk/sites/default/files/2022-02/TSD17-DSU-Observational-data-FINAL.pdf">https://www.sheffield.ac.uk/sites/default/files/2022-02/TSD17-DSU-Observational-data-FINAL.pdf</ext-link></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>S</given-names></name><name><surname>Salcher-Konrad</surname><given-names>M</given-names></name><name><surname>Boccia</surname><given-names>S</given-names></name><name><surname>Bouvy</surname><given-names>JC</given-names></name><name><surname>Waure</surname><given-names>C</given-names></name><name><surname>Espin</surname><given-names>J</given-names></name><etal/></person-group><article-title>The use of nonrandomized evidence to estimate treatment effects in health technology assessment</article-title><source>J Comp Eff Res</source><year>2021</year><volume>10</volume><issue>14</issue><fpage>1035</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.2217/cer-2021-0108</pub-id><pub-id pub-id-type="pmid">34279114</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kent S, Salcher-Konrad M, Boccia S, Bouvy JC, Waure C, Espin J, et al. The use of nonrandomized evidence to estimate treatment effects in health technology assessment. J Comp Eff Res. 2021;10(14):1035&#x02013;43.<pub-id pub-id-type="pmid">34279114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Grimson</surname><given-names>F</given-names></name><name><surname>Mihaylova</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>P</given-names></name><name><surname>Warren</surname><given-names>J</given-names></name><name><surname>van Engen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Use of External Comparators for Health Technology Assessment Submissions based on single-arm trials</article-title><source>Value Health</source><year>2021</year><volume>24</volume><issue>8</issue><fpage>1118</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2021.01.015</pub-id><pub-id pub-id-type="pmid">34372977</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Patel D, Grimson F, Mihaylova E, Wagner P, Warren J, van Engen A, et al. Use of External Comparators for Health Technology Assessment Submissions based on single-arm trials. Value Health. 2021;24(8):1118&#x02013;25.<pub-id pub-id-type="pmid">34372977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">NICE. Metreleptin for treating lipodystrophy (HST14); 2021. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/hst14">https://www.nice.org.uk/guidance/hst14</ext-link></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872); 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta872">https://www.nice.org.uk/guidance/ta872</ext-link></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">NICE. Risdiplam for treating spinal muscular atrophy (TA755); 2021. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta755">https://www.nice.org.uk/guidance/ta755</ext-link></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">NICE. Entrectinib for treating NTRK fusion-positive solid tumours (TA644); 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta644">https://www.nice.org.uk/guidance/ta644</ext-link></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Downing</surname><given-names>NS</given-names></name><name><surname>Aminawung</surname><given-names>JA</given-names></name><name><surname>Shah</surname><given-names>ND</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name></person-group><article-title>Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005&#x02013;2012</article-title><source>JAMA</source><year>2014</year><volume>311</volume><issue>4</issue><fpage>368</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.282034</pub-id><pub-id pub-id-type="pmid">24449315</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005&#x02013;2012. JAMA. 2014;311(4):368&#x02013;77.<pub-id pub-id-type="pmid">24449315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Goring</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>TJJ</given-names></name><name><surname>Korol</surname><given-names>EE</given-names></name><name><surname>Levy</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review</article-title><source>BMJ Open</source><year>2019</year><volume>9</volume><issue>2</issue><fpage>e024895</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2018-024895</pub-id><pub-id pub-id-type="pmid">30819708</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Goring S, Taylor A, Muller K, Li TJJ, Korol EE, Levy AR, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9(2):e024895.<pub-id pub-id-type="pmid">30819708</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Hatswell</surname><given-names>AJ</given-names></name><name><surname>Baio</surname><given-names>G</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Irs</surname><given-names>A</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name></person-group><article-title>Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999&#x02013;2014</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><issue>6</issue><fpage>e011666</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2016-011666</pub-id><pub-id pub-id-type="pmid">27363818</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999&#x02013;2014. BMJ Open. 2016;6(6):e011666.<pub-id pub-id-type="pmid">27363818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Naci</surname><given-names>H</given-names></name><name><surname>Salcher-Konrad</surname><given-names>M</given-names></name><name><surname>Kesselheim</surname><given-names>AS</given-names></name><name><surname>Wieseler</surname><given-names>B</given-names></name><name><surname>Rochaix</surname><given-names>L</given-names></name><name><surname>Redberg</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Generating comparative evidence on new drugs and devices before approval</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10228</issue><fpage>986</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)33178-2</pub-id><pub-id pub-id-type="pmid">32199486</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Naci H, Salcher-Konrad M, Kesselheim AS, Wieseler B, Rochaix L, Redberg RF, et al. Generating comparative evidence on new drugs and devices before approval. Lancet. 2020;395(10228):986&#x02013;97.<pub-id pub-id-type="pmid">32199486</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Tenhunen</surname><given-names>O</given-names></name><name><surname>Lasch</surname><given-names>F</given-names></name><name><surname>Schiel</surname><given-names>A</given-names></name><name><surname>Turpeinen</surname><given-names>M</given-names></name></person-group><article-title>Single-arm clinical trials as pivotal evidence for Cancer Drug approval: a retrospective cohort study of centralized European marketing authorizations between 2010 and 2019</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><issue>3</issue><fpage>653</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/cpt.1965</pub-id><pub-id pub-id-type="pmid">32578196</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Tenhunen O, Lasch F, Schiel A, Turpeinen M. Single-arm clinical trials as pivotal evidence for Cancer Drug approval: a retrospective cohort study of centralized European marketing authorizations between 2010 and 2019. Clin Pharmacol Ther. 2020;108(3):653&#x02013;60.<pub-id pub-id-type="pmid">32578196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>AD</given-names></name><name><surname>Puthumana</surname><given-names>J</given-names></name><name><surname>Downing</surname><given-names>NS</given-names></name><name><surname>Shah</surname><given-names>ND</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name></person-group><article-title>Assessment of clinical trials supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995&#x02013;2017</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>4</issue><fpage>e203284</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.3284</pub-id><pub-id pub-id-type="pmid">32315070</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of clinical trials supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995&#x02013;2017. JAMA Netw Open. 2020;3(4):e203284.<pub-id pub-id-type="pmid">32315070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Estimating causal effects of treatments in randomized and nonrandomized studies</article-title><source>J Educ Psychol</source><year>1974</year><volume>66</volume><issue>5</issue><fpage>688</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1037/h0037350</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66(5):688&#x02013;701.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Sekhon J, The Neyman&#x02014; Rubin model of causal inference and estimation via matching methods [cited 10/13/2023]. In: The Oxford handbook of political methodology [Internet]. Oxford University Press, [cited 10/13/2023]; 2008. Available from: 10.1093/oxfordhb/9780199286546.003.0011</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Naimi</surname><given-names>AI</given-names></name><name><surname>Cole</surname><given-names>SR</given-names></name><name><surname>Kennedy</surname><given-names>EH</given-names></name></person-group><article-title>An introduction to g methods</article-title><source>Int J Epidemiol</source><year>2017</year><volume>46</volume><issue>2</issue><fpage>756</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">28039382</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Naimi AI, Cole SR, Kennedy EH. An introduction to g methods. Int J Epidemiol. 2017;46(2):756&#x02013;62.<pub-id pub-id-type="pmid">28039382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Keil</surname><given-names>AP</given-names></name><name><surname>Edwards</surname><given-names>JK</given-names></name><name><surname>Richardson</surname><given-names>DB</given-names></name><name><surname>Naimi</surname><given-names>AI</given-names></name><name><surname>Cole</surname><given-names>SR</given-names></name></person-group><article-title>The parametric g-formula for time-to-event data: intuition and a worked example</article-title><source>Epidemiol (Cambridge Mass)</source><year>2014</year><volume>25</volume><issue>6</issue><fpage>889</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1097/EDE.0000000000000160</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Keil AP, Edwards JK, Richardson DB, Naimi AI, Cole SR. The parametric g-formula for time-to-event data: intuition and a worked example. Epidemiol (Cambridge Mass). 2014;25(6):889&#x02013;97.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Brookhart</surname><given-names>MA</given-names></name><name><surname>Wyss</surname><given-names>R</given-names></name><name><surname>Layton</surname><given-names>JB</given-names></name><name><surname>St&#x000fc;rmer</surname><given-names>T</given-names></name></person-group><article-title>Propensity score methods for confounding control in nonexperimental research</article-title><source>Circulation Cardiovasc Qual Outcomes</source><year>2013</year><volume>6</volume><issue>5</issue><fpage>604</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.113.000359</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Brookhart MA, Wyss R, Layton JB, St&#x000fc;rmer T. Propensity score methods for confounding control in nonexperimental research. Circulation Cardiovasc Qual Outcomes. 2013;6(5):604&#x02013;11.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuss</surname><given-names>O</given-names></name><name><surname>Blettner</surname><given-names>M</given-names></name><name><surname>B&#x000f6;rgermann</surname><given-names>J</given-names></name></person-group><article-title>Propensity score: an alternative method of analyzing Treatment effects</article-title><source>Deutsches Arzteblatt Int</source><year>2016</year><volume>113</volume><issue>35&#x02013;36</issue><fpage>597</fpage><lpage>603</lpage></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kuss O, Blettner M, B&#x000f6;rgermann J. Propensity score: an alternative method of analyzing Treatment effects. Deutsches Arzteblatt Int. 2016;113(35&#x02013;36):597&#x02013;603.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Funk</surname><given-names>MJ</given-names></name><name><surname>Westreich</surname><given-names>D</given-names></name><name><surname>Wiesen</surname><given-names>C</given-names></name><name><surname>Sturmer</surname><given-names>T</given-names></name><name><surname>Brookhart</surname><given-names>MA</given-names></name><name><surname>Davidian</surname><given-names>M</given-names></name></person-group><article-title>Doubly robust estimation of causal effects</article-title><source>Am J Epidemiol</source><year>2011</year><volume>173</volume><issue>7</issue><fpage>761</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/aje/kwq439</pub-id><pub-id pub-id-type="pmid">21385832</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Funk MJ, Westreich D, Wiesen C, Sturmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173(7):761&#x02013;7.<pub-id pub-id-type="pmid">21385832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Kreif</surname><given-names>N</given-names></name><name><surname>Grieve</surname><given-names>R</given-names></name><etal/></person-group><article-title>Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation</article-title><source>Health Serv Outcomes Res Method</source><year>2013</year><volume>12</volume><issue>2&#x02013;4</issue><fpage>174</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1007/s10742-013-0109-2</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kreif N, Grieve R, et al. Regression-adjusted matching and double-robust methods for estimating average treatment effects in health economic evaluation. Health Serv Outcomes Res Method. 2013;12(2&#x02013;4):174&#x02013;202.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Schaubel</surname><given-names>DE</given-names></name></person-group><article-title>Contrasting treatment-specific survival using double-robust estimators</article-title><source>Stat Med</source><year>2012</year><volume>31</volume><issue>30</issue><fpage>4255</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1002/sim.5511</pub-id><pub-id pub-id-type="pmid">22807175</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhang M, Schaubel DE. Contrasting treatment-specific survival using double-robust estimators. Stat Med. 2012;31(30):4255&#x02013;68.<pub-id pub-id-type="pmid">22807175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>MS</given-names></name><name><surname>Prieto-Alhambra</surname><given-names>D</given-names></name><name><surname>Lopes</surname><given-names>LC</given-names></name><name><surname>Ramos</surname><given-names>D</given-names></name><name><surname>Bispo</surname><given-names>N</given-names></name><name><surname>Ichihara</surname><given-names>MY</given-names></name><etal/></person-group><article-title>Propensity score methods in Health Technology Assessment: principles, extended applications, and recent advances</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>973</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.00973</pub-id><pub-id pub-id-type="pmid">31619986</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ali MS, Prieto-Alhambra D, Lopes LC, Ramos D, Bispo N, Ichihara MY, et al. Propensity score methods in Health Technology Assessment: principles, extended applications, and recent advances. Front Pharmacol. 2019;10:973.<pub-id pub-id-type="pmid">31619986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>DA</given-names></name></person-group><article-title>On regression adjustments to experimental data</article-title><source>Adv Appl Math</source><year>2008</year><volume>40</volume><issue>2</issue><fpage>180</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.aam.2006.12.003</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Freedman DA. On regression adjustments to experimental data. Adv Appl Math. 2008;40(2):180&#x02013;93.</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Nianogo</surname><given-names>RA</given-names></name><name><surname>Arah</surname><given-names>OA</given-names></name></person-group><article-title>G-computation of average treatment effects on the treated and the untreated</article-title><source>BMC Med Res Methodol</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s12874-016-0282-4</pub-id><pub-id pub-id-type="pmid">28068905</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wang A, Nianogo RA, Arah OA. G-computation of average treatment effects on the treated and the untreated. BMC Med Res Methodol. 2017;17(1):3.<pub-id pub-id-type="pmid">28068905</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Yu Z, van der Laan MJ. Construction of counterfactuals and the G-computation formula; 2002. Available from: <ext-link ext-link-type="uri" xlink:href="https://biostats.bepress.com/ucbbiostat/paper122/">https://biostats.bepress.com/ucbbiostat/paper122/</ext-link></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name></person-group><article-title>The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments</article-title><source>Stat Med</source><year>2014</year><volume>33</volume><issue>7</issue><fpage>1242</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/sim.5984</pub-id><pub-id pub-id-type="pmid">24122911</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242&#x02013;58.<pub-id pub-id-type="pmid">24122911</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Sekhon</surname><given-names>JS</given-names></name></person-group><article-title>Multivariate and propensity score matching Software with Automated Balance optimization: the matching package for R</article-title><source>J Stat Softw</source><year>2011</year><volume>42</volume><issue>7</issue><fpage>1</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.18637/jss.v042.i07</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sekhon JS. Multivariate and propensity score matching Software with Automated Balance optimization: the matching package for R. J Stat Softw. 2011;42(7):1&#x02013;52.</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Schuster</surname><given-names>T</given-names></name></person-group><article-title>The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study</article-title><source>Stat Methods Med Res</source><year>2016</year><volume>25</volume><issue>5</issue><fpage>2214</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1177/0962280213519716</pub-id><pub-id pub-id-type="pmid">24463885</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Austin PC, Schuster T. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study. Stat Methods Med Res. 2016;25(5):2214&#x02013;37.<pub-id pub-id-type="pmid">24463885</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>SR</given-names></name><name><surname>Hern&#x000e1;n</surname><given-names>MA</given-names></name></person-group><article-title>Adjusted survival curves with inverse probability weights</article-title><source>Comput Methods Programs Biomed</source><year>2004</year><volume>75</volume><issue>1</issue><fpage>45</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2003.10.004</pub-id><pub-id pub-id-type="pmid">15158046</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Cole SR, Hern&#x000e1;n MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75(1):45&#x02013;9.<pub-id pub-id-type="pmid">15158046</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data</article-title><source>Stat Med</source><year>2005</year><volume>24</volume><issue>20</issue><fpage>3089</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1002/sim.2174</pub-id><pub-id pub-id-type="pmid">16189810</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089&#x02013;110.<pub-id pub-id-type="pmid">16189810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>H</given-names></name><name><surname>Robins</surname><given-names>JM</given-names></name></person-group><article-title>Doubly robust estimation in missing data and causal inference models</article-title><source>Biometrics</source><year>2005</year><volume>61</volume><issue>4</issue><fpage>962</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1541-0420.2005.00377.x</pub-id><pub-id pub-id-type="pmid">16401269</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics. 2005;61(4):962&#x02013;73.<pub-id pub-id-type="pmid">16401269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Mahani AS. Combining matching and linear regression: Introducing a mathematical framework and software for simulations, diagnostics and calibration; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/MatchLinReg/vignettes/MatchLinReg.pdf">https://cran.r-project.org/web/packages/MatchLinReg/vignettes/MatchLinReg.pdf</ext-link></mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>J</given-names></name><name><surname>Cefalu</surname><given-names>M</given-names></name><name><surname>Palmer</surname><given-names>N</given-names></name><name><surname>Agniel</surname><given-names>D</given-names></name></person-group><article-title>Doubly robust matching estimators for high dimensional confounding adjustment</article-title><source>Biometrics</source><year>2018</year><volume>74</volume><issue>4</issue><fpage>1171</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/biom.12887</pub-id><pub-id pub-id-type="pmid">29750844</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Antonelli J, Cefalu M, Palmer N, Agniel D. Doubly robust matching estimators for high dimensional confounding adjustment. Biometrics. 2018;74(4):1171&#x02013;9.<pub-id pub-id-type="pmid">29750844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>JL</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name></person-group><article-title>Average causal effects from nonrandomized studies: a practical guide and simulated example</article-title><source>Psychol Methods</source><year>2008</year><volume>13</volume><issue>4</issue><fpage>279</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1037/a0014268</pub-id><pub-id pub-id-type="pmid">19071996</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Schafer JL, Kang J. Average causal effects from nonrandomized studies: a practical guide and simulated example. Psychol Methods. 2008;13(4):279&#x02013;313.<pub-id pub-id-type="pmid">19071996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Neugebauer</surname><given-names>R</given-names></name><name><surname>van der Laan</surname><given-names>M</given-names></name></person-group><article-title>Why prefer double robust estimators in causal inference?</article-title><source>J Stat Plann Inference</source><year>2005</year><volume>129</volume><issue>1</issue><fpage>405</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jspi.2004.06.060</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Neugebauer R, van der Laan M. Why prefer double robust estimators in causal inference? J Stat Plann Inference. 2005;129(1):405&#x02013;26.</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JDY</given-names></name><name><surname>Schafer</surname><given-names>JL</given-names></name></person-group><article-title>Demystifying double robustness: a comparison of alternative strategies for estimating a Population Mean from Incomplete Data</article-title><source>Stat Sci</source><year>2007</year><volume>22</volume><issue>4</issue><fpage>523</fpage><lpage>39</lpage></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Kang JDY, Schafer JL. Demystifying double robustness: a comparison of alternative strategies for estimating a Population Mean from Incomplete Data. Stat Sci. 2007;22(4):523&#x02013;39.</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>J</given-names></name><name><surname>Sued</surname><given-names>M</given-names></name><name><surname>Lei-Gomez</surname><given-names>Q</given-names></name><name><surname>Rotnitzky</surname><given-names>A</given-names></name><name><surname>Comment</surname></name></person-group><article-title>Performance of double-robust estimators when Inverse Probability weights are highly variable</article-title><source>Stat Sci</source><year>2007</year><volume>22</volume><issue>4</issue><fpage>544</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1214/07-STS227D</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Robins J, Sued M, Lei-Gomez Q, Rotnitzky A, Comment. Performance of double-robust estimators when Inverse Probability weights are highly variable. Stat Sci. 2007;22(4):544&#x02013;59.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Kreif</surname><given-names>N</given-names></name><name><surname>Gruber</surname><given-names>S</given-names></name><name><surname>Radice</surname><given-names>R</given-names></name><name><surname>Grieve</surname><given-names>R</given-names></name><name><surname>Sekhon</surname><given-names>JS</given-names></name></person-group><article-title>Evaluating treatment effectiveness under model misspecification: a comparison of targeted maximum likelihood estimation with bias-corrected matching</article-title><source>Stat Methods Med Res</source><year>2016</year><volume>25</volume><issue>5</issue><fpage>2315</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1177/0962280214521341</pub-id><pub-id pub-id-type="pmid">24525488</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Kreif N, Gruber S, Radice R, Grieve R, Sekhon JS. Evaluating treatment effectiveness under model misspecification: a comparison of targeted maximum likelihood estimation with bias-corrected matching. Stat Methods Med Res. 2016;25(5):2315&#x02013;36.<pub-id pub-id-type="pmid">24525488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Hubbard AE, van der Laan MJ, Robins JM, editors. Nonparametric locally efficient estimation of the treatment specific survival distribution with right censored data and covariates in observational studies. Statistical models in Epidemiology, the Environment, and clinical trials. New York, NY: Springer New York; 2000.</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Tsiatis</surname><given-names>AA</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>SM</given-names></name></person-group><article-title>Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling</article-title><source>Biometrics</source><year>2013</year><volume>69</volume><issue>4</issue><fpage>830</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/biom.12076</pub-id><pub-id pub-id-type="pmid">24117096</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Bai X, Tsiatis AA, O&#x02019;Brien SM. Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling. Biometrics. 2013;69(4):830&#x02013;9.<pub-id pub-id-type="pmid">24117096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Ozenne</surname><given-names>BMH</given-names></name><name><surname>Scheike</surname><given-names>TH</given-names></name><name><surname>Staerk</surname><given-names>L</given-names></name><name><surname>Gerds</surname><given-names>TA</given-names></name></person-group><article-title>On the estimation of average treatment effects with right-censored time to event outcome and competing risks</article-title><source>Biometrical J Biometrische Z</source><year>2020</year><volume>62</volume><issue>3</issue><fpage>751</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1002/bimj.201800298</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Ozenne BMH, Scheike TH, Staerk L, Gerds TA. On the estimation of average treatment effects with right-censored time to event outcome and competing risks. Biometrical J Biometrische Z. 2020;62(3):751&#x02013;63.</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>George</surname><given-names>SL</given-names></name></person-group><article-title>Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies</article-title><source>J Biopharm Stat</source><year>2019</year><volume>29</volume><issue>4</issue><fpage>592</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1080/10543406.2019.1633659</pub-id><pub-id pub-id-type="pmid">31286838</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wang X, Bai F, Pang H, George SL. Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies. J Biopharm Stat. 2019;29(4):592&#x02013;605.<pub-id pub-id-type="pmid">31286838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Lee D, Yang S, Wang X. Generalizable survival analysis of randomized controlled trials with observational studies. arXiv:220106595; 2022.</mixed-citation></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Covariate-adjusted survival analyses in propensity-score matched samples: imputing potential time-to-event outcomes</article-title><source>Stat Methods Med Res</source><year>2020</year><volume>29</volume><issue>3</issue><fpage>728</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1177/0962280218817926</pub-id><pub-id pub-id-type="pmid">30569832</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Austin PC, Thomas N, Rubin DB. Covariate-adjusted survival analyses in propensity-score matched samples: imputing potential time-to-event outcomes. Stat Methods Med Res. 2020;29(3):728&#x02013;51.<pub-id pub-id-type="pmid">30569832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>EA</given-names></name></person-group><article-title>Matching methods for causal inference: a review and a look forward</article-title><source>Stat Science: Rev J Inst Math Stat</source><year>2010</year><volume>25</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1214/09-STS313</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Science: Rev J Inst Math Stat. 2010;25(1):1&#x02013;21.</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Lunt</surname><given-names>M</given-names></name></person-group><article-title>Selecting an appropriate caliper can be essential for achieving good balance with propensity score matching</article-title><source>Am J Epidemiol</source><year>2014</year><volume>179</volume><issue>2</issue><fpage>226</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/aje/kwt212</pub-id><pub-id pub-id-type="pmid">24114655</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Lunt M. Selecting an appropriate caliper can be essential for achieving good balance with propensity score matching. Am J Epidemiol. 2014;179(2):226&#x02013;35.<pub-id pub-id-type="pmid">24114655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Imbens</surname><given-names>GW</given-names></name></person-group><article-title>Nonparametric estimation of Average Treatment effects under Exogeneity: a review</article-title><source>Rev Econ Stat</source><year>2004</year><volume>86</volume><issue>1</issue><fpage>4</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1162/003465304323023651</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Imbens GW. Nonparametric estimation of Average Treatment effects under Exogeneity: a review. Rev Econ Stat. 2004;86(1):4&#x02013;29.</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Chatton A. G-computation and inverse probability weighting for time to-event outcomes: a comparative study. arXiv:200616859v1; 2020.</mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Chatton</surname><given-names>A</given-names></name><name><surname>Borgne</surname><given-names>FL</given-names></name><name><surname>Leyrat</surname><given-names>C</given-names></name><name><surname>Foucher</surname><given-names>Y</given-names></name></person-group><article-title>G-computation and doubly robust standardisation for continuous-time data: a comparison with inverse probability weighting</article-title><source>Stat Methods Med Res</source><year>2022</year><volume>31</volume><issue>4</issue><fpage>706</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1177/09622802211047345</pub-id><pub-id pub-id-type="pmid">34861799</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Chatton A, Borgne FL, Leyrat C, Foucher Y. G-computation and doubly robust standardisation for continuous-time data: a comparison with inverse probability weighting. Stat Methods Med Res. 2022;31(4):706&#x02013;18.<pub-id pub-id-type="pmid">34861799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Noor</surname><given-names>A</given-names></name><name><surname>Mouaz</surname><given-names>A</given-names></name><name><surname>Fares</surname><given-names>A</given-names></name></person-group><article-title>New evidence pyramid</article-title><source>Evid Based Med</source><year>2016</year><volume>21</volume><issue>4</issue><fpage>125</fpage><pub-id pub-id-type="doi">10.1136/ebmed-2016-110401</pub-id><pub-id pub-id-type="pmid">27339128</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Murad MH, Noor A, Mouaz A, Fares A. New evidence pyramid. Evid Based Med. 2016;21(4):125.<pub-id pub-id-type="pmid">27339128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Rubinger L, Ekhtiari S, Gazendam A, Bhandari M. Registries: Big data, bigger problems? Injury. 2023;54 Suppl 3:S39-S42.</mixed-citation></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>LC</given-names></name><name><surname>Ersboll</surname><given-names>AK</given-names></name></person-group><article-title>When the entire population is the sample: strengths and limitations in register-based epidemiology</article-title><source>Eur J Epidemiol</source><year>2014</year><volume>29</volume><issue>8</issue><fpage>551</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10654-013-9873-0</pub-id><pub-id pub-id-type="pmid">24407880</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Thygesen LC, Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014;29(8):551&#x02013;8.<pub-id pub-id-type="pmid">24407880</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Zinzani</surname><given-names>PL</given-names></name><name><surname>Flinn</surname><given-names>IW</given-names></name><name><surname>Yuen</surname><given-names>SLS</given-names></name><name><surname>Topp</surname><given-names>MS</given-names></name><name><surname>Rusconi</surname><given-names>C</given-names></name><name><surname>Fleury</surname><given-names>I</given-names></name><etal/></person-group><article-title>Venetoclax-Rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>23</issue><fpage>2628</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">32785666</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-Rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2628&#x02013;37.<pub-id pub-id-type="pmid">32785666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Sehn</surname><given-names>LH</given-names></name><name><surname>Herrera</surname><given-names>AF</given-names></name><name><surname>Flowers</surname><given-names>CR</given-names></name><name><surname>Kamdar</surname><given-names>MK</given-names></name><name><surname>McMillan</surname><given-names>A</given-names></name><name><surname>Hertzberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Polatuzumab Vedotin in relapsed or refractory diffuse large B-Cell lymphoma</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>2</issue><fpage>155</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.00172</pub-id><pub-id pub-id-type="pmid">31693429</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38(2):155&#x02013;65.<pub-id pub-id-type="pmid">31693429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>BB</given-names></name><name><surname>Klopfer</surname><given-names>SO</given-names></name></person-group><article-title>Optimal full matching and related designs via Network flows</article-title><source>J Comput Graphical Stat</source><year>2006</year><volume>15</volume><issue>3</issue><fpage>609</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1198/106186006X137047</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Hansen BB, Klopfer SO. Optimal full matching and related designs via Network flows. J Comput Graphical Stat. 2006;15(3):609&#x02013;27.</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>A</given-names></name><name><surname>Sekhon</surname><given-names>JS</given-names></name></person-group><article-title>Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies</article-title><source>Rev Econ Stat</source><year>2013</year><volume>95</volume><issue>3</issue><fpage>932</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1162/REST_a_00318</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Diamond A, Sekhon JS. Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies. Rev Econ Stat. 2013;95(3):932&#x02013;45.</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Stuart</surname><given-names>EA</given-names></name></person-group><article-title>Optimal full matching for survival outcomes: a method that merits more widespread use</article-title><source>Stat Med</source><year>2015</year><volume>34</volume><issue>30</issue><fpage>3949</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1002/sim.6602</pub-id><pub-id pub-id-type="pmid">26250611</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Austin PC, Stuart EA. Optimal full matching for survival outcomes: a method that merits more widespread use. Stat Med. 2015;34(30):3949&#x02013;67.<pub-id pub-id-type="pmid">26250611</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>EA</given-names></name><name><surname>Green</surname><given-names>KM</given-names></name></person-group><article-title>Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes</article-title><source>Dev Psychol</source><year>2008</year><volume>44</volume><issue>2</issue><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1037/0012-1649.44.2.395</pub-id><pub-id pub-id-type="pmid">18331131</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Stuart EA, Green KM. Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes. Dev Psychol. 2008;44(2):395&#x02013;406.<pub-id pub-id-type="pmid">18331131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>JM</given-names></name><name><surname>Rassen</surname><given-names>JA</given-names></name><name><surname>Ackermann</surname><given-names>D</given-names></name><name><surname>Bartels</surname><given-names>DB</given-names></name><name><surname>Schneeweiss</surname><given-names>S</given-names></name></person-group><article-title>Metrics for covariate balance in cohort studies of causal effects</article-title><source>Stat Med</source><year>2014</year><volume>33</volume><issue>10</issue><fpage>1685</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/sim.6058</pub-id><pub-id pub-id-type="pmid">24323618</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33(10):1685&#x02013;99.<pub-id pub-id-type="pmid">24323618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>EA</given-names></name><name><surname>Lee</surname><given-names>BK</given-names></name><name><surname>Leacy</surname><given-names>FP</given-names></name></person-group><article-title>Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research</article-title><source>J Clin Epidemiol</source><year>2013</year><volume>66</volume><issue>8 Suppl</issue><fpage>S84</fpage><lpage>Se901</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.01.013</pub-id><pub-id pub-id-type="pmid">23849158</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84&#x02013;Se901.<pub-id pub-id-type="pmid">23849158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Abadie</surname><given-names>A</given-names></name><name><surname>Cattaneo</surname><given-names>MD</given-names></name></person-group><article-title>Econometric methods for program evaluation</article-title><source>Annual Rev Econ</source><year>2018</year><volume>10</volume><issue>1</issue><fpage>465</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1146/annurev-economics-080217-053402</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Abadie A, Cattaneo MD. Econometric methods for program evaluation. Annual Rev Econ. 2018;10(1):465&#x02013;503.</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Denz</surname><given-names>R</given-names></name><name><surname>Klaa&#x000df;en-Mielke</surname><given-names>R</given-names></name><name><surname>Timmesfeld</surname><given-names>N</given-names></name></person-group><article-title>A comparison of different methods to adjust survival curves for confounders</article-title><source>Stat Med</source><year>2023</year><volume>42</volume><issue>10</issue><fpage>1461</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1002/sim.9681</pub-id><pub-id pub-id-type="pmid">36748630</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Denz R, Klaa&#x000df;en-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. Stat Med. 2023;42(10):1461&#x02013;79.<pub-id pub-id-type="pmid">36748630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Gutman</surname><given-names>R</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Robust estimation of causal effects of binary treatments in unconfounded studies with dichotomous outcomes</article-title><source>Stat Med</source><year>2013</year><volume>32</volume><issue>11</issue><fpage>1795</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1002/sim.5627</pub-id><pub-id pub-id-type="pmid">23019093</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Gutman R, Rubin DB. Robust estimation of causal effects of binary treatments in unconfounded studies with dichotomous outcomes. Stat Med. 2013;32(11):1795&#x02013;814.<pub-id pub-id-type="pmid">23019093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Kleinbaum GG, Klein M. Survival analysis: a self-learning text (2nd edn.). Springer; 2006.</mixed-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Venebles WN, Ripley BD. Modern applied statistics with S(4th edn.). Springer; 2002.</mixed-citation></ref><ref id="CR80"><label>80.</label><mixed-citation publication-type="other">Burnham KP, Anderson DR. Model selection and multimodel inference. Springer; 2002.</mixed-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Rubin DB. Multiple imputation for nonresponse in surveys. Sons JW, editor. New York; 1987.</mixed-citation></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Efron</surname><given-names>B</given-names></name></person-group><article-title>Estimation and accuracy after Model Selection</article-title><source>J Am Stat Assoc</source><year>2014</year><volume>109</volume><issue>507</issue><fpage>991</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1080/01621459.2013.823775</pub-id><pub-id pub-id-type="pmid">25346558</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Efron B. Estimation and accuracy after Model Selection. J Am Stat Assoc. 2014;109(507):991&#x02013;1007.<pub-id pub-id-type="pmid">25346558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Latimer</surname><given-names>NR</given-names></name></person-group><article-title>Survival analysis for economic evaluations alongside clinical trials&#x02014;extrapolation with patient-level data: inconsistencies, limitations, and a practical guide</article-title><source>Med Decis Making</source><year>2013</year><volume>33</volume><issue>6</issue><fpage>743</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1177/0272989X12472398</pub-id><pub-id pub-id-type="pmid">23341049</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Latimer NR. Survival analysis for economic evaluations alongside clinical trials&#x02014;extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743&#x02013;54.<pub-id pub-id-type="pmid">23341049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">McGuire CJ, Wood M. A review of parametric model choice used to extrapolate RCT outcomes. Ares. 2020;5104325.</mixed-citation></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="other">Latimer N.: NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data; 2011.</mixed-citation></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Gallacher</surname><given-names>D</given-names></name><name><surname>Kimani</surname><given-names>P</given-names></name><name><surname>Stallard</surname><given-names>N</given-names></name></person-group><article-title>Extrapolating parametric survival models in health technology assessment: a simulation study</article-title><source>Med Decis Making</source><year>2021</year><volume>41</volume><issue>1</issue><fpage>37</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1177/0272989X20973201</pub-id><pub-id pub-id-type="pmid">33283635</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Gallacher D, Kimani P, Stallard N. Extrapolating parametric survival models in health technology assessment: a simulation study. Med Decis Making. 2021;41(1):37&#x02013;50.<pub-id pub-id-type="pmid">33283635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishak</surname><given-names>KJ</given-names></name><name><surname>Kreif</surname><given-names>N</given-names></name><name><surname>Benedict</surname><given-names>A</given-names></name><name><surname>Muszbek</surname><given-names>N</given-names></name></person-group><article-title>Overview of parametric survival analysis for health-economic applications</article-title><source>PharmacoEconomics</source><year>2013</year><volume>31</volume><issue>8</issue><fpage>663</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s40273-013-0064-3</pub-id><pub-id pub-id-type="pmid">23673905</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. PharmacoEconomics. 2013;31(8):663&#x02013;75.<pub-id pub-id-type="pmid">23673905</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group><source>R: a language and environment for statistical computing</source><year>2015</year><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name></element-citation><mixed-citation id="mc-CR88" publication-type="book">R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="other">Ho D, Kosuke I, King G, Stuart E, Whitworth A. Package &#x02018;MatchIt&#x02019;: nonparametric preprocessing for parametric causal inference; 2018. Available from: <ext-link ext-link-type="uri" xlink:href="https://cran.r-hub.io/web/packages/MatchIt/MatchIt.pdf">https://cran.r-hub.io/web/packages/MatchIt/MatchIt.pdf</ext-link></mixed-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">Greifer N, Cobalt. Covariate balance tables and plots. R package version 431; 2021.</mixed-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Therneau T, Lumley T, Atkinson E. C C. R package &#x02018;survival&#x02019; 2020. Available from: <ext-link ext-link-type="uri" xlink:href="https://cran.r-hub.io/web/packages/survival/index.html">https://cran.r-hub.io/web/packages/survival/index.html</ext-link></mixed-citation></ref><ref id="CR92"><label>92.</label><mixed-citation publication-type="other">Yoshida K, Claret L, Package. &#x02018;survParamSim&#x02019;; 2022. Available from: <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/survParamSim/survParamSim.pdf">https://cran.r-project.org/web/packages/survParamSim/survParamSim.pdf</ext-link></mixed-citation></ref><ref id="CR93"><label>93.</label><mixed-citation publication-type="other">van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007;6(1).</mixed-citation></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name></person-group><article-title>Using ensemble-based methods for directly estimating Causal effects: an investigation of Tree-based G-Computation</article-title><source>Multivar Behav Res</source><year>2012</year><volume>47</volume><issue>1</issue><fpage>115</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1080/00273171.2012.640600</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Austin PC. Using ensemble-based methods for directly estimating Causal effects: an investigation of Tree-based G-Computation. Multivar Behav Res. 2012;47(1):115&#x02013;35.</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Westreich</surname><given-names>D</given-names></name><name><surname>Lessler</surname><given-names>J</given-names></name><name><surname>Funk</surname><given-names>MJ</given-names></name></person-group><article-title>Propensity score estimation: neural networks, support vector machines, decision trees (CART), and meta-classifiers as alternatives to logistic regression</article-title><source>J Clin Epidemiol</source><year>2010</year><volume>63</volume><issue>8</issue><fpage>826</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2009.11.020</pub-id><pub-id pub-id-type="pmid">20630332</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Westreich D, Lessler J, Funk MJ. Propensity score estimation: neural networks, support vector machines, decision trees (CART), and meta-classifiers as alternatives to logistic regression. J Clin Epidemiol. 2010;63(8):826&#x02013;33.<pub-id pub-id-type="pmid">20630332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>J</given-names></name><name><surname>Lengline</surname><given-names>E</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Thiebaut</surname><given-names>R</given-names></name><name><surname>Zohar</surname><given-names>S</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name></person-group><article-title>Enriching single-arm clinical trials with external controls: possibilities and pitfalls</article-title><source>Blood Adv</source><year>2023</year><volume>7</volume><issue>19</issue><fpage>5680</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2022009167</pub-id><pub-id pub-id-type="pmid">36534147</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Lambert J, Lengline E, Porcher R, Thiebaut R, Zohar S, Chevret S. Enriching single-arm clinical trials with external controls: possibilities and pitfalls. Blood Adv. 2023;7(19):5680&#x02013;90.<pub-id pub-id-type="pmid">36534147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TL</given-names></name><name><surname>Collins</surname><given-names>GS</given-names></name><name><surname>Spence</surname><given-names>J</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Daures</surname><given-names>JP</given-names></name><name><surname>Landais</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparison of the ability of double-robust estimators to correct bias in propensity score matching analysis. A Monte Carlo simulation study</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2017</year><volume>26</volume><issue>12</issue><fpage>1513</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/pds.4325</pub-id><pub-id pub-id-type="pmid">28984050</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Nguyen TL, Collins GS, Spence J, Devereaux PJ, Daures JP, Landais P, et al. Comparison of the ability of double-robust estimators to correct bias in propensity score matching analysis. A Monte Carlo simulation study. Pharmacoepidemiol Drug Saf. 2017;26(12):1513&#x02013;9.<pub-id pub-id-type="pmid">28984050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name></person-group><article-title>Estimating adjusted risk differences by multiply-imputing missing control binary potential outcomes following propensity score-matching</article-title><source>Stat Med</source><year>2021</year><volume>40</volume><issue>25</issue><fpage>5565</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/sim.9141</pub-id><pub-id pub-id-type="pmid">34374106</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Austin PC, Rubin DB, Thomas N. Estimating adjusted risk differences by multiply-imputing missing control binary potential outcomes following propensity score-matching. Stat Med. 2021;40(25):5565&#x02013;86.<pub-id pub-id-type="pmid">34374106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">NICE. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments; 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta927">https://www.nice.org.uk/guidance/ta927</ext-link></mixed-citation></ref></ref-list></back></article>